Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19.

Hannah B KnoxLisa A DykesLancer A ScottBradley C PresleyLara C Lambert

Published in: The Annals of pharmacotherapy (2024)

Overall, the mAbs appeared safe and effective. Sicker, higher-risk mAb-treated veterans faired similarly to less-sick, high-risk veterans not treated. Those who were vaccinated seemed to benefit the most from mAb therapy. Future prospective studies with more matched groups are needed to assess full benefits and risks of mAbs shown to neutralize the predominant variants.

Keyphrases

monoclonal antibody
coronavirus disease
sars cov
high intensity
newly diagnosed
risk assessment
human health
gene expression
mesenchymal stem cells
respiratory syndrome coronavirus
replacement therapy